Perioperative anesthesia management of GLP-1 receptor agonists: a systematic review of potential risks
They found that participants lost an average of 15.1% of their total body weight over a 68-week period
Patients should discuss weight management concerns with their GP and report any adverse effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk
For weekly GLP-1 medications, the window to take a missed dose varies by product: semaglutide (Ozempic) allows 5 days, semaglutide (Wegovy) allows 2 days, dulaglutide (Trulicity) allows 3 days, and tirzepatide (Mounjaro/Zepbound) allows 4 days
However, patients taking them alongside other diabetes medications (particularly insulin or sulphonylureas) have an increased risk of hypoglycaemic episodes, which commonly present with fatigue, weakness, and confusion
7 Lastly, investigational agents hold promise for new anti-obesity therapies that may sustain weight loss or minimize weight regain
